Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Aug;36(4):317-39.
doi: 10.1007/s10928-009-9124-x. Epub 2009 Jun 27.

Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm

Affiliations

Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm

Julie Bertrand et al. J Pharmacokinet Pharmacodyn. 2009 Aug.

Abstract

Pharmacogenetics is now widely investigated and health institutions acknowledge its place in clinical pharmacokinetics. Our objective is to assess through a simulation study, the impact of design on the statistical performances of three different tests used for analysis of pharmacogenetic information with nonlinear mixed effects models: (i) an ANOVA to test the relationship between the empirical Bayes estimates of the model parameter of interest and the genetic covariate, (ii) a global Wald test to assess whether estimates for the gene effect are significant, and (iii) a likelihood ratio test (LRT) between the model with and without the genetic covariate. We use the stochastic EM algorithm (SAEM) implemented in MONOLIX 2.1 software. The simulation setting is inspired from a real pharmacokinetic study. We investigate four designs with N the number of subjects and n the number of samples per subject: (i) N = 40/n = 4, similar to the original study, (ii) N = 80/n = 2 sorted in 4 groups, a design optimized using the PFIM software, (iii) a combined design, N = 20/n = 4 plus N = 80 with only a trough concentration and (iv) N = 200/n = 4, to approach asymptotic conditions. We find that the ANOVA has a correct type I error estimate regardless of design, however the sparser design was optimized. The type I error of the Wald test and LRT are moderatly inflated in the designs far from the asymptotic (<10%). For each design, the corrected power is analogous for the three tests. Among the three designs with a total of 160 observations, the design N = 80/n = 2 optimized with PFIM provides both the lowest standard error on the effect coefficients and the best power for the Wald test and the LRT while a high shrinkage decreases the power of the ANOVA. In conclusion, a correction method should be used for model-based tests in pharmacogenetic studies with reduced sample size and/or sparse sampling and, for the same amount of samples, some designs have better power than others.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Mean simulated concentration-time curve and allocation of the sampling times within each of the designs N=40/n=4, N=80/n=2, N=100/n=4,1 and N=200/n=4 (separated by solid horizontal lines): the vertical lines denote the four possible sampling times, the dashed horizontal lines join samples within the same group and the circles size is proportional to the sample size within each elementary design.
Fig 2
Fig 2
Concentrations (ng/mL) simulated for the designs N=40/n=4 (left), N=80/n=2 (center) and N=100/n=4,1 (right) for a representative data set under H0 (top) and a representative one under H1 (bottom). Solid lines represent the subjects CC while dashed and dotted lines represent the subjects CT and TT for the exon SNP1, respectively. For the N=100/n=4,1 design, circles represent the subjects CC while triangles and plus represent the subjects CT and TT for the exon SNP1, respectively.
Fig 3
Fig 3
(a) Boxplot of shrinkage on V/F from Mbase obtained with SAEM on the 1000 data sets simulated under H0 (grey) and H1 (black) for the designs N=40/n=4, N=80/n=2, N=100/n=4,1 and N=200/n=4, (b) type I error for the ANOVA on the log-parameters versus the empirical shrinkage on V/F for the designs N=40/n=4 (○), N=80/n=2 (△), N=100/n=4,1 (+) and N=200/n=4 (×) simulated under H0, (c) Corrected power of the ANOVA on the log-parameters versus the empirical shrinkage on V/F for the designs N=40/n=4 (○), N=80/n=2 (△) and N=100/n=4,1 (+) simulated under H1.
Fig 4
Fig 4
(a) Boxplot of the estimated standard errors (SE) and corresponding empirical SE (dotted line) obtained with SAEM for β1 and β2 on the 1000 data sets simulated under both H0 (grey) and H1 (black) for the N=40/n=4, N=80/n=2, N=100/n=4,1 and N=200/n=4 designs, (b) Wald test type I error versus the ratio of the median SE over the empirical SE for β2 for the designs N=40/n=4 (○), N=80/n=2 (△), N=100/n=4,1 (+) and N=200/n=4 (×) simulated under H0, (c) Wald test corrected power versus the empirical SE for β2 for the designs N=40/n=4 (○), N=80/n=2 (△) and N=100/n=4,1 (+) simulated under H1.
Fig 5
Fig 5
Histograms of the likelihood ratio test (LRT) statistics above the theoretical threshold (5.99) obtained with SAEM under H0 for the N=40/n=4, N=80/n=2, N=100/n=4,1 and N=200/n=4 designs. The dotted curve corresponds to the density of a χ2 with 2 degrees of freedom.
Fig 6
Fig 6
Standard errors versus the estimates for β1 and β2 obtained with FOCE-I in NONMEM version V (a) and (b) and SAEM in MONOLIX version 2.1 (c) and (d) for the design N=40/n=4 simulated under H1. Note that βFOCEI1 and βFOCEI2 correspond respectively to eβSAEM1 and eβSAEM2, therefore the scales are different.

References

    1. EMEA. Technical report. EMEA; 2008. ICH topic E15 definitions for genomic biomarkers, pharmacogenomics, pharmacogenetics, genomic data and sample coding categories.
    1. FDA. Technical report. FDA; 2008. E15 definitions for genomic biomarkers, pharmacogenomics, pharmacogenetics, genomic data and sample coding categories.
    1. EMEA. Technical report. EMEA; 2007. Reflection paper on the use of pharmacogenetics in the pharmacokinetic evaluation of medicinal products.
    1. Hu XP, Xu JM, Hu YM, Mei Q, Xu XH. Effects of CYP2C19 genetic polymorphism on the pharmacokinetics and pharmacodynamics of omeprazole in chinese people. J Clin Pharmacol Ther. 2007;32:517–524. - PubMed
    1. Hirt D, Mentré F, Tran A, Rey E, Auleley S, Salmon D, Duval X, Tréluyer JM the COPHAR2-ANRS Study Group. Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients. Br J Clin Pharmacol. 2008;65:548–57. - PMC - PubMed

Publication types